We have analyzed the interaction of the adhesive glycoprotein, von Willebrand factor (vWF), with native monomeric collagen monolayers by adsorbing acid soluble Types I and III collagen derived from calf skin to polystyrene microtiter wells and incubating the wells with purified human '25I-vWF. 
Introduction
von Willebrand Factor (vWF)' plays an important role in the initial adhesion of platelets to vascular subendothelium (1, 2) . Because of the polymeric nature ofthe vWF protein, its relatively low plasma concentration, and the complexity of the subendothelial matrix, the nature of vWF binding to subendothelial matrix components has not yet been fully defined. Previous studies of the interaction of vWF, platelets, and denuded subendothelium have utilized everted vessel segments (1, 3, 4) , matrix produced by cultured endothelial cells (5, 6) , and monoclonal antibodies to selected vWF epitopes (1, 4) . These studies have clearly demonstrated that vWF binds to subendothelium. In addition, selective protease digestion has implicated collagen as one potential binding site for plasma vWF (4) (5) (6) . Several inves- 1 . Abbreviations used in this paper: C lq, the q subunit of the first component of complement; PAGE, polyacrylamide gel electrophoresis; PEG, polyethylene glycol; TBS, 10-15 ml of 0.05 M Tris, 0.15 M NaCl, 0.02% sodium azide, pH 7.4; vWF, von Willebrand Factor. tigators have reported the binding of vWF to suspensions of microfibrillar collagen (7-1 1), while others have suggested that vWF binds to noncollagenous microfibrils extracted from bovine aortae ( 12) or to noncollagenous constituents in the matrix derived from cultured endothelial cells (13) .
While some of these reports clearly demonstrate an interaction between vWF and collagen, the biochemical nature of the interaction is not understood. The form of collagen used in some binding assays may differ from the collagen present in vascular subendothelium. In vivo, collagen is present as a surface network of discrete bundles interwoven with other extracellular matrix constituents, including fibronectin, laminin, and certain species ofglycosaminoglycans (14) (15) (16) (17) . There may also be a role for additional adhesive glycoproteins like fibronectin, fibrinogen, and thrombospondin in vWF-collagen or vWF-platelet interactions. Finally, there are no studies that compare the binding characteristics of the platelet granule, plasma, and subendothelial pools of vWF, nor is there any information on possible mechanisms to stabilize the interaction of vWF with matrix proteins like collagen or laminin.
Fibrin (18) , fibronectin (19) , and a2 antiplasmin (20) are three substrates for Factor XIIIa. There is a specific cross-linking domain on fibronectin, separate from the collagen-binding domain, that is cross-linked to collagen (21, 22) . As a first step toward understanding the complex interactions that regulate vWF binding to subendothelium, we have developed methods to quantitate vWF binding to purified monomeric collagen and have defined a highly specific reversible interaction with collagen.
In addition, we have demonstrated the formation of irreversible vWF-collagen cross-links catalyzed by Factor XIIIa.
Methods
Immulon I microtiter wells were obtained from Dynatech Laboratories, Inc., Alexandria, VA. The following reagents were used: Iodobeads (Pierce Chemical Co., Rockford, IL); '25I-Na (New England Nuclear, Boston, MA); Sephacryl S 1000 and Sepharose CL6B (Pharmacia Fine Chemicals, Piscataway, NJ); Affi-gel Gelatin Sepharose, high molecular weight standards, and sodium dodecyl sulfate (SDS) (Bio-Rad Laboratories, Richmond, CA); acid-soluble calfskin collagen (Worthington Diagnostics Div., Millipore Corp., Freehold, NJ); mouse laminin (Bethesda Research Laboratories, Gaithersburg, MD); ristocetin (Bio/Data Corp., Horsham, PA); bovine thrombin (Miles Laboratories, Elkhart, IN); type III gelatin, bovine serum albumin (BSA), gamma globulin, fibrinogen, polyethylene glycol relative molecular weight (Mr) 8,000 and Mr 20,000, dithiothreitol (DTT), EDTA, and beta-mercaptoethanol (Sigma Chemical Co., St. Louis, MO). Purified Clq was obtained from CalBiochem-Behring Corp., La Jolla, CA. Purified human fibronectin and purified Factor XIII were prepared as previously described (23, 24) . Identical results were obtained with highly purified Factor XIII and with a product of intermediate purity (containing albumin). Hence, the intermediate product was used for many experiments. All other chemicals were reagent grade or better.
vWF purification. vWF was purified by a modification of the pro-gion (Boston, MA), frozen at -20'C for 24 h, and thawed at 4VC for 18 h, was used as the starting material rather than partially purified commercial VIII concentrates. The resulting cryoprecipitate was collected by centrifugation at 6,500 g for 20 min, resuspended in 20 mM Na citrate, pH 6.1, and reprecipitated twice with final concentrations of 5 and 12% polyethylene glycol (PEG) as previously described (25) . The final precipitate was collected by centrifugation at 6,500 g for 20 min, the pellet surface was washed twice with ice cold 0.02 M Tris 0.15 M NaCl, 8% ethanol, pH 7.4 to remove residual PEG, and resuspended in 10-15 ml of 0.05 M Tris, 0.15 M NaCl, 0.02% sodium azide, pH 7.4 (TBS) and applied to a 2.5 X 90 cm siliconized glass column containing Sephacryl S 1000. 4-ml fractions, collected at a 70 ml per hour flow rate, were analyzed for ristocetin-dependent platelet-agglutinating activity, protein concentration by the method of Lowry (26) , and for purity by 5% SDS-polyacrylamide gel electrophoresis (PAGE) (27) after disulfide bond reduction, as described below. Those fractions exhibiting both maximal ristocetin cofactor activity per milligram protein and demonstrating a single 220,000-molecular-weight band on 5% SDS-PAGE were pooled and concentrated by dialysis against 20% PEG (Mr, 20,000). Purified vWF was stored frozen at -20'C in 250-MAl aliquots for up to 3 wk.
Iodination ofvWF and collagen. To remove any contaminating fibronectin (27) , 300 Ag of purified vWF were chromatographed on a 1-ml column of gelatin Sepharose preequilibrated with TBS. Fractions of the flow through volume containing ristocetin cofactor activity were pooled before iodination. 500 ,ug of acid-soluble calf skin collagen were dialyzed extensively against distilled water at 4°C. The dialysate was divided into 100-ug aliquots, frozen rapidly in a dry ice-acetone bath, lyophilized, and stored at -20°C until further use. Immediately before iodination, the Iyophilized collagen was resuspended in 1 ml TBS and left on ice. Both proteins were labeled with the iodobead technique. In each case, one iodobead was preincubated for 10 min with 0.5-1 mCi '25I-Na, followed by addition of 100 Mg vWF. After 10 min at room temperature, iodination was stopped by transfer of the vWF solution to a 0.7 X 10 cm Sephadex G-25 column preequilibrated with 1 mg/ml BSA in TBS and eluted with TBS. Typical specific radioactivity of vWF was 0.20-0.23 MCi/Mg protein. vWF retained 90% of its initial platelet agglutinating activity after iodination. 251I-vWF also co-migrated with unlabeled vWF as a single band (Mr 220,000) on 5% SDS-PAGE after disulfide reduction. Radiolabeled vWF was used within 3 d of iodination.
After 15 min, the radiolabeled collagen solution was dialyzed exhaustively for 48 h against 0.05 M acetic acid. Radiolabeled collagen typically had a specific activity of0.17-0.20 ,Ci/Mgg and, at a concentration of 8 Mg/ml, was capable of inducing aggregation of platelet-rich plasma equivalent to that ofa 10 ,g/ml solution ofunlabeled collagen. 5% SDS-PAGE (27) of reduced radiolabeled collagen showed four major bands with molecular weights consistent with the a,, a2, and (i-chains of calf skin collagen and trace (<1%) contamination with fibronectin.
Collagen-coated plates. An extract of calf skin containing -60% type I and 40% type III collagen was diluted in 0.05 M acetic acid to 1.87 mg/ml. 100-Ml aliquots of this collagen solution were added to individual flat-bottomed microtiter wells and incubated for 1.5 h at room temperature. The solution was then removed by gentle aspiration, and the wells were washed once with 1 mg/ml BSA in TBS, decanted, and then refilled completely with the albumin solution. After 1 h incubation at room temperature, the albumin solution was completely removed by gentle suction, and the plates were immediately used for vWF binding assays. In some experiments, acid-soluble collagen was denatured by heating in 0.05 M acetic acid for 1 h at 60°C. Wells containing other extracellular matrix constituents were prepared in a fashion similar to that described for collagen. All stock solutions offibronectin, fibrinogen, albumin, gamma globulin, and Clq were diluted to 2.5 mg/ml in TBS.
Quantitation ofcollagen bound to wells. Sufficient '251I-collagen was added to 1.87 mg/ml of nonradioactive collagen to give a final specific radioactivity of 0.45 MCi/mg, and serial dilutions were made from this stock solution. Concentrations of '251-collagen from 0.47 mg/ml to 1.87 mg/ml were then incubated in flat-bottomed microtiter wells as previously described for 0.5 to 3 h at 4 and 250C to optimize binding conditions. At the highest concentration, 10 Mg collagen bound to each well. All incubations were terminated by aspiration of unbound radiolabeled collagen, and plates were washed and coated with albumin solutions as described above. Individual microtiter wells were detached, and total bound radiolabeled collagen was determined in a Gamma 8000 Spectrometer (Beckman Instruments, Inc., Fullerton, CA). Unless otherwise specified, all collagen-coated plates were typically prepared using a stock collagen solution of 1.87 mg/ml and a 90-min incubation period at room temperature. Binding ofgelatin to microtiter plates was assessed by using heat-denatured radiolabeled collagen. vWF binding assay. Varying concentrations of 1251I-vWF were added to collagen-coated wells in the presence or absence of a 20-fold excess of nonradiolabeled vWF. Additional TBS was added to make the final volume 100 Al, and samples were incubated for 1 h at room temperature.
The incubation was terminated by gentle aspiration of unbound vWF, and wells were washed three times with TBS. Bound radiolabeled vWF was determined by counting individual wells as described above. Specifically bound vWF was defined as total bound radioactivity minus radioactivity bound in wells containing a 20-fold excess of nonlabeled vWF.
Factor XIIIa cross-linking ofvWF in collagen-coated wells. In some experiments, intermediate purity Factor XIII containing 0.5 mg/ml albumin was activated with 5 U/ml bovine thrombin in the presence of 10 mM calcium and 4 mM dithiothreitol for 20 min at 370C. Thrombin was inactivated by addition of the irreversible inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) (28) before use ofthe activated Factor XIII (XIIIa) in assays. 1 Ag/ml 1251I-vWF was incubated with Factor XIIIa in the presence or absence of EDTA in parallel collagencoated wells for 60 min at room temperature. After dilution, the final concentration of DTT varied from 0.4 to 0.6 mM. Incubation of vWF with this concentration of DTT did not change vWF multimer distribution when analyzed by SDS-agarose gel electrophoresis. The wells were then aspirated, washed twice with TBS containing 15 mM EDTA, and bound radioactivity was measured. To determine whether the '251-vWF was covalently bound to the collagen-coated wells, a 100-fold excess of nonlabeled vWF in TBS 5 mM EDTA, pH 7.4, or TBS 5 mM EDTA, pH 7.4 alone was added to the remaining duplicate wells. The wells were incubated for an additional 45 min to permit the added vWF to displace any noncovalently bound 251I-vWF. Wells were then aspirated and washed three times with 5 mM EDTA and bound radioactivity was measured.
Factor platelets/Mi in TBS (29) . The ability ofnative vWF polymers to agglutinate formalin-fixed platelets was determined in the presence of 1 mg/ml ristocetin (30, 31) , and agglutination was monitored on a dual-channel aggregometer (Payton Assoc., Inc., Buffalo, NY).
Results
As shown in Fig. 1 (Fig. 2) , reaching equilibrium at 1 h. The binding of '251-vWF was reversed by the addition of a 100-fold excess of unlabeled vWF. 45% of the bound radiolabeled vWF was rapidly dissociated from collagen within 10 min of adding a 100-fold excess of vWF to incubations in which the binding of '251I-vWF reached equilibrium (Fig. 2) . Further dissociation ofbound vWF from collagen occurred more slowly, with -15% of bound vWF remaining at 2 h. In wells in which only buffer 1.0. -0 (Fig. 3) . The lack of binding of radiolabeled vWF to denatured collagen was not due to a decreased binding of denatured collagen to microtiter wells since studies using radiolabeled collagen indicated the binding to be similar (10 ,ug/well for native collagen vs. 8 tg/well for denatured collagen). In addition, there was no demonstrable binding to wells coated with Clq, a component of human complement with amino acid sequences and tertiary structural similarities to collagen (32) .
Since there is an 80-fold higher concentration of fibronectin and fibrinogen in plasma when compared to vWF, we examined their effects on vWF binding to collagen. Fig. 4 shows that neither fibronectin nor fibrinogen, in concentrations ranging from 2.4 to 240 pg/ml, competed for the binding of 4 ,gg/ml 1251-vWF to collagen. The IC50 for vWF in these competition experiments was 8-1 1 ,tg/ml, consistent with the half-maximal binding at 5 jig/ml estimated in Fig. 1 from the direct binding of 251I-vWF to collagen.
We then studied the effects of incubating vWF and collagen in the presence of Factor XIIIa (Table I) . After the addition of Factor XIIIa, but in the presence ofthe calcium chelator EDTA, 100 ,g/ml nonradioactive vWF displaced 90% ofthe bound 1251I vWF, the same as in controls without Factor XIIIa. In contrast, in those wells incubated in the presence of Factor XIIIa without 
220-

200-
16-
92 --the inhibitor EDTA, only 47% ofbound '251-vWF was displaced by the same concentration of nonlabeled vWF. In addition, the total amount ofvWF bound to wells in the presence ofactivated Factor XIIIa was 2.7 times that bound in wells incubated in the presence of Factor XIIIa and EDTA or in controls. This was not due to an effect ofEDTA on the binding ofvWF to collagen, since incubations containing 15 mM EDTA, in the absence of Factor XIIa, were similar to that seen in control wells containing no Factor XMa or EDTA (Table I) . Fig. 5 shows the results of incubating '25I-vWF and Factor XIII with three subendothelial proteins. Lanes 2-6 show a progressive, time-dependent loss of the 220,000 Mr vWF subunit and the appearance of higher molecular weight species only in the presence of2.5 U/ml Factor XIIIa. These cross-linked species are reflected in the radioactive bands that do not enter the gel or remain at the interface between the stacking and running gel. This change in electrophoretic mobility is most consistent with Factor XIIIa-dependent-cross-linking of vWF to collagen. Ad- t Noncovalently bound '251-vWF was displaced by the addition of 100 ig/mI nonlabeled vWF and the wells were washed twice with TBS. Figure 5 . Autoradiographic analysis of Factor XIIIa-dependent crosslinking of vWF to selected subendothelial proteins on 4.3% SDS-PAGE. 10 g/ml '25I-vWF, 2.5 U/ml Factor XIIIa, 0.4-0.6 mM DTT, and 10 mM calcium were incubated with buffer, 100 jg/ml calfskin collagen, 100 jg/ml laminin, or 200 jg/ml fibronectin for up to 6 h at room temperature as described in Methods. Lane 1, collagen, '"IvWF, 5 mM EDTA, Factor XIIIa 6 h incubation; lanes 2-6, collagen, '25I-vWF, Factor XIIIa incubated for 0.5, 1, 2, 4, and 6 h, respectively; lane 7, Factor XIIIa and '25I-vWF 6 h incubation; lane 8, fibronectin, '25I-vWF, and Factor XIIIa, 6 h incubation; lane 9, laminin, '25I-vWF, and Factor XIIIa 6 h incubation. Lanes 7, 8, and 9 were selected from three separate gels, accounting for the variation in the size of the stacking gel and mobility of the 220,000-mol-wt band. Standards: purified vWF, 220,000; myosin heavy chain, 200,000; fl-galactosidase, 116,000; phosphorylase B, 92,000. The dried gel was exposed to x-ray film for 48 h. dition of 5 mM EDTA inhibits cross-linking of vWF to collagen (lane 1). In the absence ofcollagen, only trace quantities ofvWF were cross-linked into higher molecular weight forms. The band appearing at 200,000-mol-wt may represent the cross-linking of partially degraded vWF polymer which yields low Mr polypeptide subunits.
To examine the specificity of cross-linking of vWF to collagen, we examined the ability ofFactor XIIIa to cross-link vWF to laminin and fibronectin, two other subendothelial proteins that do not interact with vWF. As shown in Fig. 5 , lanes 8 and 9, vWF cannot be cross-linked to laminin or fibronectin. These results strongly suggest that vWF is covalently bound to collagen in the presence of activated Factor XIII and calcium.
Discussion
In these studies, we have shown the highly selective nature of vWF binding and its covalent cross-linking to collagen. Previous investigators have assessed vWF binding to collagen by measuring the depletion of plasma vWF by microfibrillar collagen (7-li plying a need for a specific quaternary structure. However, vWF can also bind to segment long spacing (SLS) forms of collagen and to type V collagen (10, 33) , which are not fibrillar. This suggests that the apparent requirement for collagen fibrils might be related to an inability to separate bound from free vWF by centrifugal techniques. There is also evidence that both the collagen subtype and the molecular form of the collagen influence vWF binding and that vWF may preferentially bind to fibrillar collagen (33, 34) .
We have now shown that vWF binds saturably and reversibly to immobilized monomeric types I and III collagen with halfmaximal binding at 5 ,g/ml, a concentration that approximates the plasma concentration of vWF (10 ,g/ml). At saturation, 75 ng of vWF were bound to the 10 uig of collagen monomer adsorbed to each microtiter well. This stoichiometry between vWF and collagen is similar to that reported by Santoro (7, 9) , who used fibrillar collagen, and found that 600 gg of microfibrillar collagen could deplete vWF antigen and activity from 0.5 ml of plasma. Assuming an average plasma vWF concentration of 10 ,gg/ml, this would represent binding ofa total of 5 (36) . These data support our observation that vWF interacts with collagen. We have not yet compared the binding capacities of purified collagen subtypes in our assay, nor have we varied the physical form of the collagen. Nevertheless, it is tempting to speculate that the binding and covalent cross-linking of vWF to collagen may facilitate vWF-mediated platelet adhesion by increasing the effective concentration of vWF at sites of vascular injury.
